Hemoglobin D Punjab (HbD) Mutation Study in UAE | 800 AED | DHA Licensed

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 Accredited Allele‑Specific PCR & Sanger Confirmation.

Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection for whole blood (Available daily 8 AM–11 PM). Invasive prenatal samples require hospital extraction.

Clinical Guidance: Telephonic Post‑Test Clinical Counseling with a DHA‑Licensed Expert for result interpretation.

Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731

Executive Summary: The Hemoglobin D Punjab (HbD) Mutation Study is a definitive genetic test that identifies the exact DNA variant responsible for hemoglobin D trait or disease. This analysis empowers precise clinical diagnosis, carrier screening, and informed reproductive planning using advanced molecular technology. Price: 800 AED. Turnaround: 7–8 working days. DHA Facility License: 1143.

Test Overview & Methodology

The Hemoglobin D Punjab (HbD) Mutation Study targets the specific HBB gene variant c.364G>C (p.Glu122Gln) responsible for hemoglobin D Punjab. This assay confirms carrier status, differentiates HbD Punjab from other hemoglobin D variants, and rules out compound inherited disorders. The test uses Allele‑Specific End‑Point PCR followed by Dual Sanger Confirmation, delivering unequivocal genotyping results.

Feature	Our Test	Standard Alternative
Methodology	Allele‑Specific End‑Point PCR + Dual Sanger Confirmation (ISO 15189:2022)	Hemoglobin Electrophoresis / HPLC (often misses silent HbD trait)
Diagnostic Precision	99.9% sensitivity; unequivocal genotyping of HbD‑Punjab vs. other D variants	~85% sensitivity; may require follow‑up gene sequencing
Turnaround Time	7–8 working days (expedited reporting available)	10–14 days with external referral

Physician Insight & Safety Protocols

“The HbD Punjab mutation is often clinically silent in the heterozygous state, yet it can masquerade as other hemoglobinopathies on routine electrophoresis. This molecular test eliminates diagnostic ambiguity, allowing precise risk stratification for reproductive counseling and clinical management. A laboratory finding must always be correlated with the complete hematologic and clinical profile.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory on Medication Continuity

⚠️ Advisory

Do not discontinue or adjust any prescribed medication such as hydroxyurea or iron chelators based solely on this test result without explicit consultation with your treating physician.

Exclusion Criteria & Emergency Red Flags

Recent Blood Transfusion: Wait at least 4 weeks post‑transfusion for peripheral blood collection to avoid donor DNA interference.
Invasive Prenatal Samples: Amniotic fluid or chorionic villi must be collected by a qualified obstetrician under sterile conditions; maternal cell contamination risk must be assessed.
Inadequate Sample: Clotted, haemolysed, or insufficient volume specimens will be rejected; a repeat collection will be scheduled promptly.
ER Red Flag: If you experience sudden severe pallor, splenic pain, chest pain, or shortness of breath, seek immediate emergency care – do not wait for test results.

Patient FAQ & Clinical Guidance

1. What does the HbD Punjab mutation study detect?

The HbD Punjab mutation study targets the specific HBB gene variant c.364G>C (p.Glu122Gln) responsible for hemoglobin D Punjab, confirming carrier status, differentiating it from other hemoglobin D variants, and ruling out compound inherited disorders.

2. Do I need a doctor’s prescription for this test?

A valid physician prescription is mandatory for diagnostic purposes; however, prescription is not required for surgical clearance, routine pregnancy sickle‑cell screening, or travel‑related fitness certificates.

3. How should I prepare for the sample collection?

No fasting is required for whole blood draw; for amniotic fluid or chorionic villus sampling, your obstetrician will follow strict aseptic protocols and provide any specific preparation instructions.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE operates under DHA Facility License Number 1143 and complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is handled with strict confidentiality, encrypted storage, and access controls. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Your results are shared only with you and your designated physician.

Clinical & Logistical Metadata

Test Name	Hemoglobin D Punjab (HbD) Mutation Study
Price (AED)	800
Turnaround Time	7–8 working days
Sample Type / Matrix	Whole Blood (EDTA), Amniotic Fluid, Chorionic Villi, or Cord Blood. VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection for whole blood (daily 8 AM–11 PM). Invasive prenatal samples require hospital extraction only.
Methodology Used	Allele‑Specific End‑Point PCR + Dual Sanger Confirmation (ISO 15189:2022)
ICD-10-CM Code	D58.2
LOINC Code	48768-3
DHA Facility License & Laboratory Address	DHA Facility License Number: 1143. Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. DNA Labs UAE.